UA94032C2 - Жидкая стабализированная композиция интерферона без hsa - Google Patents

Жидкая стабализированная композиция интерферона без hsa

Info

Publication number
UA94032C2
UA94032C2 UAA200704143A UAA200704143A UA94032C2 UA 94032 C2 UA94032 C2 UA 94032C2 UA A200704143 A UAA200704143 A UA A200704143A UA A200704143 A UAA200704143 A UA A200704143A UA 94032 C2 UA94032 C2 UA 94032C2
Authority
UA
Ukraine
Prior art keywords
liquid formulations
stabilized interferon
interferon
interferon liquid
stabilized
Prior art date
Application number
UAA200704143A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фабрицио Самаритани
Рио Алессандра Дель
Original Assignee
Эйрес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйрес Трейдинг С.А. filed Critical Эйрес Трейдинг С.А.
Publication of UA94032C2 publication Critical patent/UA94032C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается стабилизированной жидкой фармацевтической композиции без HSA, содержащей интерферон-бета (IFN-бета), которая представляет собой раствор, содержащий буфер, поверхностно-активное вещество, каким является полоксамер 188, изотонический агент, бактериостатический препарат, которым является бензиловый спирт, и антиоксидант, которым является метионин.
UAA200704143A 2003-05-01 2004-04-29 Жидкая стабализированная композиция интерферона без hsa UA94032C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03101210 2003-05-01

Publications (1)

Publication Number Publication Date
UA94032C2 true UA94032C2 (ru) 2011-04-11

Family

ID=36908159

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200509798A UA80331C2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilised interferon liquid formulations
UAA200704143A UA94032C2 (ru) 2003-05-01 2004-04-29 Жидкая стабализированная композиция интерферона без hsa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200509798A UA80331C2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilised interferon liquid formulations

Country Status (28)

Country Link
US (1) US8309069B2 (ru)
EP (1) EP1617861B1 (ru)
JP (2) JP4870550B2 (ru)
KR (1) KR101116058B1 (ru)
CN (1) CN1816347B (ru)
AR (1) AR044147A1 (ru)
AU (2) AU2004233603B2 (ru)
BR (1) BRPI0410488B8 (ru)
CA (1) CA2521560A1 (ru)
DK (1) DK1617861T3 (ru)
EA (2) EA200800327A1 (ru)
ES (1) ES2417061T3 (ru)
HR (1) HRP20130512T1 (ru)
IL (1) IL171709A (ru)
ME (1) ME00404B (ru)
MX (1) MXPA05011718A (ru)
MY (1) MY151121A (ru)
NO (1) NO335674B1 (ru)
NZ (2) NZ566625A (ru)
PL (1) PL1617861T3 (ru)
PT (1) PT1617861E (ru)
RS (1) RS52869B (ru)
SG (1) SG159389A1 (ru)
SI (1) SI1617861T1 (ru)
TW (1) TWI272948B (ru)
UA (2) UA80331C2 (ru)
WO (1) WO2004096263A2 (ru)
ZA (2) ZA200508124B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110699T1 (hr) * 2003-12-11 2011-10-31 Ares Trading S.A. Stabilne tekuće formulacije interferona
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
ZA200800253B (en) * 2005-09-14 2009-05-27 Ares Trading Sa Method for the quantitative determination of poloxamers
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
LT2134353T (lt) * 2007-03-30 2017-03-27 Xisle Pharma Ventures Trust Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
CA2888442A1 (en) 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of peginterferon alpha-2b
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5858001A (en) * 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
DE69936409T2 (de) 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
ES2288021T3 (es) * 1998-05-11 2007-12-16 Basf Aktiengesellschaft Metodo para la produccion de isoxazolina-3-il-acil benceno.
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
HRP20110699T1 (hr) 2003-12-11 2011-10-31 Ares Trading S.A. Stabilne tekuće formulacije interferona
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков

Also Published As

Publication number Publication date
BRPI0410488B1 (pt) 2021-06-22
NO335674B1 (no) 2015-01-19
RS20050821A (sr) 2007-12-31
IL171709A (en) 2016-03-31
NZ542912A (en) 2008-04-30
PT1617861E (pt) 2013-08-28
KR101116058B1 (ko) 2012-04-12
UA80331C2 (en) 2007-09-10
JP2011225599A (ja) 2011-11-10
MY151121A (en) 2014-04-30
AU2004233603B2 (en) 2009-02-26
ME00404B (me) 2011-10-10
KR20060011976A (ko) 2006-02-06
JP5346065B2 (ja) 2013-11-20
HK1088847A1 (zh) 2006-11-17
DK1617861T3 (da) 2013-07-29
CA2521560A1 (en) 2004-11-11
EP1617861A2 (en) 2006-01-25
ES2417061T3 (es) 2013-08-05
WO2004096263A3 (en) 2004-12-02
US20070059285A1 (en) 2007-03-15
SG159389A1 (en) 2010-03-30
AU2009201261A1 (en) 2009-04-23
WO2004096263A2 (en) 2004-11-11
TW200503754A (en) 2005-02-01
MXPA05011718A (es) 2006-01-23
CN1816347B (zh) 2010-07-21
ZA200508124B (en) 2009-02-25
SI1617861T1 (sl) 2013-09-30
EA200501699A1 (ru) 2006-06-30
US8309069B2 (en) 2012-11-13
RS52869B (sr) 2013-12-31
EA200800327A1 (ru) 2008-10-30
HRP20130512T1 (hr) 2013-07-31
JP2006525280A (ja) 2006-11-09
EP1617861B1 (en) 2013-05-29
ZA200708484B (en) 2008-10-29
BRPI0410488A (pt) 2006-06-13
TWI272948B (en) 2007-02-11
CN1816347A (zh) 2006-08-09
NO20055666L (no) 2005-11-30
AU2004233603A1 (en) 2004-11-11
EA009995B1 (ru) 2008-06-30
NZ566625A (en) 2010-02-26
PL1617861T3 (pl) 2013-10-31
AR044147A1 (es) 2005-08-24
JP4870550B2 (ja) 2012-02-08
BRPI0410488B8 (pt) 2021-09-08
MEP60408A (en) 2011-05-10

Similar Documents

Publication Publication Date Title
TW200503754A (en) HSA-free stabilized interferon liquid formulations
NO20065860L (no) Stabiliserte flytende interferonformuleringer
UA93349C2 (ru) Способ стабилизации мономерного белка интерферона
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
MY142354A (en) Acidic insulin preparations having improved stability
PT1412384E (pt) Formulação estável de glp-1 modificado
EA200000629A1 (ru) Стабилизированные растворы терипаратида
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
NZ593190A (en) Factor viii formulations
HRP20100727T1 (hr) Tekući ili liofilizirani farmaceutski pripravci fsh i/ili lh zajedno s neionskim tenzidom poloksamer 188 i bakteriostatskim sredstvom
IL206441A0 (en) Peg-interferon-beta formulations and their preparation
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
SI1691825T1 (sl) Stabilizirane tekoäśe farmacevtske oblike interferona
WO2003028624A3 (en) Levothyroxine compositions and methods
AR034749A1 (es) Formulaciones de interferon beta humano
AU3739500A (en) Protease resistant flint analogs
TW200501977A (en) Stabilized composition comprising protein
WO2004014318A3 (en) Levothyroxine compositions and methods
TH102367B (th) สูตรผสมอินเตอร์เฟียรอนที่เป็นของเหลวซึ่งถูกทำให้เสถียรโดยปลอด hsa
IL149899A0 (en) MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HCl AS ACTIVE SUBSTANCE
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη